Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576492 | 1.00 | PLAU (0.45) | PLAUMTNR1AMTNR1BEPHX2SIGMAR1 | |
| SCHEMBL2030277 | 1.00 | PLAU (0.45) | PLAUMTNR1AMTNR1BEPHX2SIGMAR1 | |
| SCHEMBL3825586 | 1.00 | PLAU (0.45) | PLAUMTNR1AMTNR1BEPHX2SIGMAR1 | |
| SCHEMBL7507376 | 0.80 | PLAU (0.52) | PLAUMTNR1AMTNR1BSIGMAR1ALOX15 | |
| SCHEMBL9024447 | 0.80 | PLAU (0.52) | PLAUALOX15HSD17B10MEN1KMT2A | |
| SCHEMBL4703041 | 0.80 | PLAU (0.52) | PLAUALOX15HSD17B10MEN1KMT2A | |
| SCHEMBL29350964 | 0.80 | PLAU (0.52) | PLAUALOX15HSD17B10MEN1KMT2A | |
| SCHEMBL3913695 | 0.80 | KDM1A (0.38) | PLAUALOX15HSD17B10MEN1KMT2A | |
| SCHEMBL9691688 | 0.77 | MAPT (0.41) | PLAUALOX15HSD17B10MEN1KMT2A | |
| SCHEMBL4014104 | 0.75 | MTNR1A (0.44) | MTNR1AMTNR1BEPHX2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2021249417-A1 | HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| CN-113272305-A | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | PLAU 4799/4885MTNR1A 16/4885MTNR1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.